Shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) surged 5.98% in after-hours trading on Wednesday following the release of its first-quarter 2025 financial results. The leading platform for medication savings in the U.S. reported in-line revenue and beat expectations on adjusted EBITDA, while also raising its full-year adjusted EBITDA guidance.

For the first quarter, GoodRx reported revenue of $203.0 million, meeting analyst estimates. The company's adjusted EBITDA came in at $69.8 million, surpassing the expected $67 million. Notably, the adjusted EBITDA margin reached 34.4%, exceeding previous guidance and demonstrating improved profitability.

Investors were particularly encouraged by GoodRx's outlook. While maintaining its full-year 2025 revenue guidance range of $810 to $840 million, the company raised its adjusted EBITDA expectations. For the second quarter, management anticipates revenue to increase sequentially from Q1's $203 million, with an adjusted EBITDA margin similar to the first quarter's strong performance. This positive outlook, combined with the better-than-expected Q1 results, likely fueled the after-hours stock price jump as investors showed increased confidence in GoodRx's growth trajectory and profitability potential.